Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7092038 | 0.89 | LMNA (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6534698 | 0.87 | CYP1A2 (0.62) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8331353 | 0.86 | NR4A2 (0.69) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8612030 | 0.85 | RAB9A (0.58) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8407027 | 0.85 | LMNA (0.51) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2553979 | 0.84 | LMNA (0.51) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL9424295 | 0.84 | MAOB (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8390694 | 0.83 | CYP4F2 (0.56) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL28646599 | 0.82 | RAB9A (0.52) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL7094039 | 0.82 | NR4A2 (0.72) | NR4A1NR4A2NR4A3MAOBPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8325237-A | — | — | None | — | — | JP | disclosed |
| US-6737124-B2 | ESPECIALLY DISILANES | DISPLAYTECH, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20030003245-A1 | Liquid crystal compounds having a silane tail with a perfluoroalkyl terminal portion | CITIZEN FINETECH MIYOTA CO., LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| EP-0821050-B1 | Optically active compound and antiferroelectric liquid crystal composition containing the same | SEMICONDUCTOR ENERGY LAB (JP) | 2001-11-28 | — | — | EP | disclosed |
| EP-0745592-B1 | Optically active pyrimidine derivatives and antiferroelectric liquid crystal compositions containing the same | SEMICONDUCTOR ENERGY LAB (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-5820782-A | LOW THRESHOLD VOLTAGE AND LOW VISCOSITY; PYRIMIDINE-BASED COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-10-13 | — | — | US | disclosed |
| EP-0821050-A1 | Optically active compound and antiferroelectric liquid crystal composition containing the same | Takasago International Corporation (JP) | 1998-01-28 | — | — | EP | disclosed |
| US-5667722-A | Antiferroelectric liquid crystal compound and antiferroelectric liquid crystal composition containing the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1997-09-16 | — | — | US | disclosed |
| EP-0754685-A2 | Derivatives from alkoxyalkoxy substituted nitrogen containing hetero rings | Rolic AG (CH) | 1997-01-22 | — | — | EP | disclosed |
| JP-H08325237-A | ANTIFERROELECTRIC LIQUID CRYSTAL COMPOUND AND ANTIFERROELECTRIC LIQUID CRYSTAL COMPOSITION CONTAINING THE COMPOUND | TAKASAGO INTERNATL CORP | 1996-12-10 | — | — | JP | disclosed |
| EP-0745592-A1 | Antiferroelectric liquid crystal compound and antiferroelectric liquid crystal composition containing the same | Takasago International Corporation (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0665837-A1 | METHOD OF PREPARING HYDROXY-SUBSTITUTED AROMATIC HETERO-COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994010153-A1 | METHOD OF PREPARING HYDROXY-SUBSTITUTED AROMATIC HETERO-COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-05-11 | — | — | WO | disclosed |
| US-5290477-A | Fluoroalkyl phenoxy containing pyrimidine-type compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030003245-A1 | Liquid crystal compounds having a silane tail with a perfluoroalkyl terminal portion | FFAR3, FFAR1, LPAR1 | LMNA 825/4885CYP1A2 2713/4885PTGS1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.